ARTICLE SUMMARY:
For clinicians treating acute stroke, early evidence suggests that the nature of the brain-blocking clot should dictate the choice of revascularization strategy. To arm clinicians with the knowledge they need before they begin a thrombectomy procedure, Sensome has developed the first over-the-guidewire sensor that reveals clot composition, an innovation recently recognized as Breakthrough by the FDA.
The FDA Breakthrough Device Designation is designed to help smooth the way for companies developing innovative products for life-threatening or irreversibly debilitating diseases, which certainly applies to acute ischemic stroke, the second leading cause of mortality and the third leading cause of disability across the globe. The agency thus recognized stroke start-up Sensome SAS (Massy, France) in late June, which will soon begin first-in-human trials of a sensor on a guidewire that could, in real time, tell clinicians what kind of blood clot they’re dealing with before they embark on a thrombectomy procedure.
